SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Tuesday reported a loss of $26 million in its first quarter.
The Salt Lake City-based company said it had a loss of 29 cents per share. Losses, adjusted for non-recurring costs and stock option expense, were 1 cent per share.
The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share.
The molecular diagnostic company posted revenue of $202.2 million in the period, also exceeding Street forecasts. Five analysts surveyed by Zacks expected $193.4 million.
Myriad expects full-year revenue in the range of $820 million to $840 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN
Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
